Abstract
Background: There is increasing adoption of neoadjuvant chemotherapy in patients undergoing surgical resection for pancreatic cancer (PC) to ensure receipt of systemic therapy in addition to surgery for optimal outcomes. However, with receipt of systemic treatment in neoadjuvant setting, the role of giving adjuvant chemotherapy in addition to neoadjuvant i.e., perioperative chemotherapy, remains controversial.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: HPB : the official journal of the International Hepato Pancreato Biliary Association
Paper Title
Journal
Date
